The RxView Blog

Real world data, analytics, and insights for healthcare decision makers

Advera Health Analytics, Inc.

How to Make Sense of the ADA Conference Data Deluge

Posted by Jim Davis on June 16, 2016

Every June, on the heels of the ASCO annual conference, comes the American Diabetes Association (ADA) annual conference, with a data deluge that is difficult for even the most diligent industry watchers to keep up with. At time of writing, it is only midday on Tuesday and there are already huge headlines from the conference.

Read More

Topics: Diabetes, Clinical Evidence, Evidex

Evidex Use Case: Analysis of DPP-4 Inhibitors

Posted by Andrea Demakas on March 24, 2016

Last week we officially launched our revamped platform Evidex, which now includes easy-to-navigate evidence from both clinical trial data and real-world adverse event reports. To give you an idea of how simple it is to complete a thorough drug review in this platform, I'll go through a step-by-step overview of how to compare multiple diabetes meds.

Read More

Topics: Diabetes

Could Diabetes Patients’ Safety Been Improved if the SGLT2 – Ketoacidosis Link Were Known Sooner?

Posted by Jim Davis on December 11, 2015

ashp_keith_with_poster-532765-edited.jpgReceiving Medwatch emails from FDA are an exciting thing around Advera Health. Though a bit morose, when we see that drug safety warning pop into our Inbox with FDA’s logo, we must admit to getting a little giddy. On Friday, FDA issued their second safety communication around the SGLT2 class of diabetes drugs and a serious (and very costly) side effect of those drugs, a condition called ketoacidosis. Ketoacidosis is a very serious condition that can lead to diabetic coma or even death. In this communication it was revealed that the FDA finally added ketoacidosis as an adverse event to the drugs’ labels, following an initial communication in May that they were evaluating the risk.

Read More

Topics: FDA, Diabetes, SGLT2

4 Conclusions on the Comparative Safety of Diabetes Drugs

Posted by Jim Davis on April 18, 2014


Last week I wrote about constructing a framework for comparable safety research (CSR) to compliment the work being done ­­­­with comparable effectiveness research (CER). Careful and continuous post-approval monitoring is vital to the evaluation of a drug’s safety profile, and with the proper framework and tools in place can be done quite easily.

A great example of what a CSR framework looks like can be found in our recent special report, The Comparative Safety of Type 2 Diabetes Medications.

Read More

Topics: Diabetes, Type 2 Diabetes Mellitus Drugs, GLP-1 Inhibitor, CSR, SLGT2 Inhibitors, DPP-4 Inhibitor

Subscribe to Email Updates